Press Releases

Press Releases

Date Title  
Apr 18, 2021
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of -3.33 points Improvement
Apr 15, 2021
Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021
DUBLIN, Ireland , April 15, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that results
Apr 07, 2021
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , April 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that in
Apr 05, 2021
Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
Dr. Garren’s extensive expertise and successful track record of advancing neurology and rare disease programs through late-stage development, registration and launch supports Company’s transition to a fully-integrated R&D and commercial business DUBLIN, Ireland , April 05, 2021 (GLOBE NEWSWIRE) --
Mar 24, 2021
Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares
DUBLIN, Ireland , March 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that it
Mar 23, 2021
Prothena Announces Proposed Offering of Ordinary Shares
DUBLIN, Ireland , March 23, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that it has
Mar 08, 2021
Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
Superior profile of novel anti-tau antibody PRX005 supports advancement for the potential treatment of Alzheimer’s disease New analyses of prasinezumab continue to support potential disease modifying effect of prasinezumab in Parkinson’s disease; Roche expected to initiate Phase 2b PADOVA study in
Feb 24, 2021
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s disease New pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early
Feb 11, 2021
Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
Net cash used in operating and investing activities was $19.1 million in the fourth quarter and $80.6 million for the full year 2020; quarter-end cash and restricted cash position of $298.1 million provides funding to advance the R&D pipeline Announced confirmatory Phase 3 AFFIRM-AL study of
Feb 05, 2021
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Feb. 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that in